Please ensure Javascript is enabled for purposes of website accessibility

Why ADMA Biologics Is Tumbling 13.5% Today

By Todd Campbell - Feb 7, 2020 at 12:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's secondary stock offering was priced below its prior-day closing price.

What happened

After announcing it had priced an up-sized secondary offering of its shares at $3.50 per share, ADMA Biologics (ADMA 2.52%) shares tumbled 13.5% at 12:15 p.m. EST on Friday.

So what

A commercial-stage biotech company, ADMA Biologics markets Bivigam and Asceniv, two plasma-derived, polyclonal, intravenous immune globulin (IVIG) products that won FDA approval in 2019. These products provide antibodies necessary to combat illness caused by bacteria and viruses in patients with primary humoral immunodeficiency (PI), a rare genetically caused immune disease.

A man looking through binoculars.

Image source: Getty Images.

In the fourth quarter, ADMA Biologics' revenue was $11.9 million, up 193% year over year, according to preliminary financial results reported on Jan. 9.

In addition to ramping commercialization of its IVIG products, ADMA Biologics is also looking to serve other drugmakers manufacturing plasma-derived products. On Jan. 7, it announced it had signed a multiyear deal with an undisclosed drug maker to supply them with plasma fractions unnecessary for making Bivigam and Asceniv. These fractions can be used to make other therapeutics, such as factor VIII replacement therapies for hemophilia A.

In a bid to sure-up its balance sheet in support of its commercial-stage strategy, management announced a $75 million stock offering on Feb. 6. After the closing bell, it announced it had priced the offering at $3.50 per share,  which is below yesterday's $4 closing price. It also said that it had increased the size of its offering to $82.3 million, before fees.

Now what

Dilutive offerings are common in biotech and, arguably, secondary stock offerings are a preferential way to raise money given that traditional bank loans can include restrictive covenants and costly interest payments.

Unlike some companies that raise money in support of research efforts, ADMA Biologics already has two fast-growing products on the market and its contract manufacturing business could be significant. Its recently signed supply deal is expected to generate over $5 million in annual revenue, with the potential to grow to over $10 million annually beginning 2022. Given ADMA Biologics estimates peak sales of its products could exceed $250 million annually, it seems prudent to raise money to support investments in its business.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ADMA Biologics, Inc. Stock Quote
ADMA Biologics, Inc.
$2.03 (2.52%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.